tapering

patient

Akebia Therapeutics Inc.

board

Lack of integrity he said to people here TBLT will go to 1.22 prereverse split.. 183 pathetic scam, he said from his heart please just kick his ass out of your boards..

$AKBA Going to be disappointment on board today.

This board is a dumpster fire filled with a bunch of amateurs who have no clue how biotech regulatory processes actually work.

So much BS on the board I don’t even wanna go through it to find the posts of substance.

Idiots on this board only wanting to make money and don&#39;t care about the safety issues.

Whole army of paid clowns appearing, board is poisoned.

$AKBA this board sucks today.. so much garbage and random people

$AKBA The current optimism of this board suddenly has me uneasy!!

When the board starts acting like this, it’s never a good sign.

but already looking like another big mistake to add to my list of big mistakes..!

$AKBA Definitely doesn’t look good, big volume!

$AKBA Company is one big failure after another.

$AKBA fukk i hate this feeling of fomo, so sad i didnt load up big sub 0.3, i would love to stack up now

If there really are big dark pool buys, Something is definitely up.

$AKBA  not even trying to expect something big.

cancer

Hazard ratios for Dapro quite bad fri malignancy, skin premalignant disorders, hypoplastic anemias, breast malignancy tumors, colorectal, prostrate, and especially renal neoplasms.

In contrast, in the NDD population, daprodustat appears to have several other important risks in addition to the risks of heart failure and bleeding gastric erosions.

Their hazard ratios are much higher than 1 meaning that very much Dapro has a propensity to cancer compared to esas.

level

$AKBA I see who apparently accept and like free speech being subjected to this level of personal attacks.

You’ll know because all the scratches will be hub cap level!

$AKBA at adcom do u know if there was any word of why gsk limited their Hb levels to essentially 10.5 not even 11 whereas other drugs vad and Roxa went up to 12 for Hb thusly gsk DD artificially looks a lot safer than it really is.

trap

Was it a bear trap by JB, or is he playing games again?

$AKBA pre-market is a Bull trap 
 
In my opinion and no advice.

$AKBA Love how they dropped the price during the last second of trading to taper the technical indicators, making it less overbought and leaving room for continued accumulation.

I’m still very bullish on Vad long term as a treatment knowing this patient population well and having reviewed trial data for all HIF-PHIs and ESAs (current SOC),

We anticipate that UTHealth will initiate an ARDS study with vadadustat in a broader patient population.&quot; 
To me, these are very positive data that will most probably drive significantly up the company value.

But, also considering this, the price of treatment with Vadadusta could be 75% less expensive than Roxadustat.

$AKBA FDA, please listen and read:

“The benefit of Vafseo is its ability to correct haemoglobin levels in dialysis-dependent patients, with effects comparable to those seen with erythropoiesis-stimulating agents.

Anemia associated with chronic kidney disease is a significant global health issue, and vadadustat is a highly effective treatment option that could lead to significant revenue growth for Akebia.

I think here we are all agree the pharma works perfect without adverse events in DD patients, and looks like approval for this group of patients should be fairly correct. Right?

news

takes a LITTLE BIT more time very very well worth it …” Was Butler telegraphing how much time is left for the release of news that will create a parabolic move?

$AKBA when we get good news im getting  my lady pregnant!!!!. .again!!

I’m assuming this one will be very positive with EU partnership news.

seem really cheap with all the potential news coming. .

That would fry any naked short and short and would shoot up stock price to the floor it should be at, with this positive chmp and soon to be formal ema approval news, that is $5 a share, minimum.

And some are saying oh its just an opinion, this is actually fantastic news for us and will open the door to other countries for approval and HOPEFULLY the US fda will approve it.

share

Shares gained +283.6% since the last report https://tinyurl.com/y6823mqe

There goes all the compliance problems in one straight shot and those shares would be worth a ton more.

I have about 234k shares and im already up 120%

$AKBA - great news, 

Ended up getting 60,500 shares for just under $40k in my lotto account.

$AKBA Loved seeing my shares in the green for a few minutes.

$AKBA What a great time to add a few more shares.

Im up around 190% and i stil havnt sold a single share

$AKBA great day, actually great week, will not sell or trim a single share until $3+ 
 
I have great confidence in her for another 300%+ 
 
.26 --&gt; 3.00+, what a biotech small cap beauty!

$AKBA I keep buying 10 and 20 shares lol I have like 50 usd of buy power left 💪

YouTube link in my profile bio. Arc community is a helpful and friendly community filled with triple digit track record traders &amp; educational content, free community room (link in bio)

This is quite good. https://www.chartmill.com/stock/quote/AKBA/fundamental-analysis?key=a33c7a6e-2162-4da3-a2d6-37296dc486fb&amp;utm_source=stocktwits&amp;utm_medium=FA&amp;utm_content=AKBA&amp;utm_campaign=social_tracking

Vadadustat DD met efficacy &amp; safety endpoints.

Also, don’t forget Vadadustat DD met efficacy &amp; safety endpoints.

&amp; if that takes LITTLE BIT more time … very, very well spent.

concerning Vadadustat will be best outcome for us (Akebia, AKBA) &amp; product (Vadadustat) &amp; he is very pleased,

The Q&amp;A employs terms such as “multiple commercial parties, deal, best outcome for us &amp; product, little bit of time, very pleased.” The Q&amp;A also uses “it’s” or “it” four times and “process” five times.

Call, Butler answered Robert Hatlett’s (industry analyst) question by using following terms &amp; words: multiple commercial parties, best outcome for us/product, little bit of time, very pleased.

CHMP positive opinion is very value creating for us &amp; having an authorization creates more value … ultimately as you get to deal.

Top Stocks matching your search for "tapering patient"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

AKBA

Akebia Therapeutics Inc.

-38.05%

$1.13 - $0.70

Dec, 17, 2022

AKBA

Akebia Therapeutics Inc.

-38.05%

$1.13 - $0.70

Dec, 17, 2022